NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive Announces First Quarter 2017 Financial Results

SAN DIEGO, April 25, 2017 /PRNewswire/ -- NuVasive, Inc. (Nasdaq: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today financial results for the quarter ended March 31, 2017. 

First Quarter 2017 Highlights

  • Revenue increased 16.2% to $250 million, or 16.0% on a constant currency basis;
  • GAAP operating profit margin of 9.3%; Non-GAAP operating profit margin of 14.1%;
  • GAAP diluted earnings per share of $0.22; Non-GAAP diluted earnings per share increase of 11.8% to $0.38; and
  • Expanded existing revolving line of credit from $150 million up to $500 million.

"NuVasive is off to a solid start to the year, with our International business exceeding our expectations, and we saw momentum building in our U.S. business as we exited the quarter," said Gregory T. Lucier, chairman and chief executive officer of NuVasive. "We are on track to deliver non–GAAP operating profit margin expansion of at least 100 basis points in 2017, reflecting our continued focus on operational efficiencies and the ramp up of our in-house manufacturing facility. Coupled with several innovative product and systems launches planned for 2017, including LessRay designed for radiation reduction, RELINE Trauma system, expandable cages and UNYTE system for complex fractures, we anticipate strong revenue acceleration for the balance of the year."

The Company also announced it amended its existing revolving line of credit to expand the facility from $150 million up to $500 million. The credit facility amendment demonstrates the Company's opportunistic approach to its capital structure, and provides for a five-year term at reasonable borrowing rates. The Company expects the expanded facility to allow greater flexibility in planning for the maturity of its convertible notes due July 2017, and support future investment in organic and inorganic growth initiatives.

A full reconciliation of GAAP to non-GAAP measures can be found in the tables of this news release.

First Quarter 2017 Results

NuVasive reported first quarter 2017 total revenue of $249.9 million, a 16.2% increase compared to $215.1 million for the first quarter 2016. On a constant currency basis, first quarter 2017 total revenue increased 16.0% compared to the same period last year. 

For the first quarter 2017, both GAAP and non-GAAP gross profit was $188.3 million, and both GAAP and non-GAAP gross margin was 75.3%. These results compared to GAAP and non-GAAP gross profit of $160.9 million and $165.8 million, respectively, and GAAP and non-GAAP gross margin of 74.8% and 77.1% respectively, for the first quarter 2016. The lower gross margin profile year-over-year is primarily driven by the expense profile of the Biotronic NeuroNetwork business acquired in July 2016. Total GAAP and non-GAAP operating expenses were $165.0 million and $152.9 million, respectively, for the first quarter of 2017. These results compared to GAAP and non-GAAP operating expenses of $148.6 million and $135.5 million, respectively, for the first quarter 2016.

The Company reported a GAAP net income of $12.8 million, or $0.22 per share, for the first quarter 2017 compared to a GAAP net loss of ($3.4) million, or ($0.07) per share, for the first quarter 2016. On a non-GAAP basis, the Company reported net income of $20.0 million, or $0.38 per share, for the first quarter 2017 compared to net income of $17.2 million, or $0.34 per share, for the first quarter 2016. 

Cash, cash equivalents and short and long-term marketable securities were approximately $134 million at March 31, 2017.

Annual Financial Guidance for 2017

The Company reiterated its full year 2017 guidance:











2017 Guidance 1



(in Million's; except %'s and EPS)


 GAAP 


 Non-GAAP 



Revenue


$  1,065


$          1,065



  % Growth - Reported


10.7%


10.7%



% Growth - Constant Currency 2




11.7%



Operating margin


12.3%


17.1%



Earnings per share


$    1.13


$            2.00



EBITDA


23.6%


26.7%



Tax Rate


~34%


~35%









1

Current guidance reflects guidance provided April 25, 2017.


2

Constant currency is a measure that adjusts US GAAP revenue for the
impact of currency over the same period in the prior year.









 

  • Revenue of $1.065 billion, which includes approximately $10 million in year-over-year currency headwinds, and reflects 10.7% growth on a reported basis and 11.7% growth on a constant currency basis compared to revenue of $962.1 million for 2016;
  • Non-GAAP diluted earnings per share of $2.00, an increase of 20% compared to non-GAAP diluted earnings per share of $1.66 for 2016;
  • Non-GAAP operating profit margin of 17.1%, an increase of 100 basis points compared to 16.1% for 2016; and
  • Adjusted EBITDA margin of 26.7%, an increase of 150 basis points compared to 25.2% for 2016.

Supplementary Financial Information

For additional financial detail, please visit the Investor Relations section of the Company's website at www.nuvasive.com to access Supplementary Financial Information.









Reconciliation of Full Year EPS Guidance





2017 Guidance




2016 Actuals


Prior 1, 2


Current 1, 3



GAAP net income per share

$  0.69


$    1.16


$         1.13



Impact of change to diluted share count

0.02


0.07


0.07



GAAP net income per share, adjusted to diluted Non-GAAP share count

$  0.71


$    1.23


$         1.20



Litigation liability gain

(0.83)


-


-



Business transition costs 4

0.35


0.05


0.04



Non-cash interest expense on convertible notes

0.38


0.33


0.33



Non-cash purchase accounting adjustments on acquisitions 5

0.28


-


-



Loss on repurchase of convertible notes

0.37


-


-



Amortization of intangible assets 6

0.78


0.83


0.89



Tax effect of adjustments 7

(0.38)


(0.44)


(0.46)



Non-GAAP earnings per share

$  1.66


$    2.00


$         2.00











GAAP Weighted shares outstanding - basic

50,077


50,967


50,967



GAAP Weighted shares outstanding - diluted

54,102


56,269


56,269



Non-GAAP Weighted shares outstanding - diluted

51,981


53,069


53,069










1

Prior guidance provided February 9, 2017.  Current guidance reflects guidance provided April 25, 2017.


2

Effective tax expense rate of ~35% applied to GAAP earnings and ~35% applied to Non-GAAP earnings.


3

Effective tax expense rate of ~34% applied to GAAP earnings and ~35% applied to Non-GAAP earnings.


4

Costs related to acquisition, integration and business transition activities which include severance, relocation,
consulting, leasehold exit costs, third party merger and acquisitions costs and other costs directly associated with such
activities.


5

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market
value adjustments, which are amortized over the period in which underlying products are sold.


6

Excludes the amortization associated with non-controlling interest.







7

The impact on results from taxes include tax effecting the adjustments above at the statutory rate as well as taking into
account discrete items and including those discrete items in the annual effective tax rate calculation. The Company also
includes those adjustments that would have benefited the tax rate in lieu of the above adjustments as part of the
Company's tax filings. The impact of the changes to the tax rate results in an annual estimated rate of ~35% on a non-
GAAP basis. 










 










Reconciliation of Non-GAAP Operating Margin %















2017 Guidance



(in thousands, except %)


2016
Actuals


Prior 1


Current 1



Non-GAAP Gross Margin %[A]


76.6%


76.1%


76.1%



Non-cash purchase accounting adjustments on acquisitions 2


(1.5%)


0.0%


0.0%



GAAP Gross Margin [B]


75.0%


76.1%


76.1%












GAAP & Non-GAAP Sales, Marketing & Administrative Expense [C]


55.5%


54.0%


54.0%












Non-GAAP Research & Development Expense [D]


5.0%


5.0%


5.0%



In-process research & development


0.0%


0.0%


0.0%



GAAP Research & Development Expense [E]


5.0%


5.0%


5.0%












Litigation liability [F]


(4.5%)


0.0%


0.0%



Amortization of intangible assets [G] 3


4.4%


4.3%


4.6%



Business transition costs [H] 4


1.9%


0.3%


0.2%












Non-GAAP Operating Margin % [A - C - D]


16.1%


17.1%


17.1%












GAAP Operating Margin % [B - C - E - F - G - H]


12.8%


12.6%


12.3%











1

Prior guidance provided February 9, 2017.  Current guidance reflects guidance provided April 25, 2017.


2

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair
market value adjustments, which are amortized over the period in which underlying products are sold.


3

Excludes the amortization associated with non-controlling interest.


4

Costs related to acquisition, integration and business transition activities which include severance,
relocation, consulting, leasehold exit costs, third party merger and acquisitions costs and other costs directly
associated with such activities.











 

Reconciliation of EBITDA %





















 2017 Guidance 



(in thousands, except %)

2016
Actuals


Prior 1


Current 1



Net Income / (Loss)

3.9%


6.1%


6.0%



Interest (income) / expense, net 2

6.1%


3.5%


3.5%



Provision for income taxes

3.0%


3.1%


3.0%



Depreciation and amortization 3

10.5%


10.8%


11.1%



EBITDA

23.5%


23.6%


23.6%



Non-cash stock based compensation

2.8%


2.9%


3.0%



Business transition costs 4

1.9%


0.3%


0.2%



Non-cash purchase accounting adjustments on acquisitions 5

1.5%


0.0%


0.0%



In-process research & development

0.0%


0.0%


0.0%



Litigation liability gain

(4.5%)


0.0%


0.0%



Adjusted EBITDA

25.2%


26.7%


26.7%










1

Prior guidance provided February 9, 2017.  Current guidance reflects guidance provided April 25, 2017.

2

Interest (income) / expense, net for the quarter and year ended December 31, 2016 includes loss on
extinguishment of debt for $1.6 million and $19.1 million, respectively.


3

Excludes the amortization associated with non-controlling interest.


4

Costs related to acquisition, integration and business transition activities which include severance, relocation,
consulting, leasehold exit costs, third party merger and acquisitions costs and other costs directly associated
with such activities.


5

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair
market value adjustments, which are amortized over the period in which underlying products are sold.










Reconciliation of Non-GAAP Information

Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, leasehold related charges, integration related expenses associated with acquired businesses, one-time restructuring and acquisition related items, CEO transition related costs, certain litigation charges and non-cash interest expense (excluding debt issuance cost) and or losses on convertible notes. Management also uses certain non-GAAP measures which are intended to exclude the impact of foreign exchange currency fluctuations. The measure constant currency is the use of an exchange rate that eliminates fluctuations when calculating financial performance numbers.

The Company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital. Additionally, the Company uses an adjusted EBITDA measure which represents earnings before interest, taxes, depreciation and amortization and excludes the impact of stock-based compensation, purchase accounting related changes, leasehold related charges, integration related expenses associated with acquired businesses, CEO transition related costs, certain litigation liabilities, acquisition related items and other significant one-time items. Management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measure.
















Reconciliation of First Quarter 2017 Results



GAAP Net Income to Adjusted EBITDA











Three months ended






(in thousands, except per share data)

March 31, 2017






GAAP net income

$                     12,768






Interest expense/(income), net

9,662






Provision for income taxes

1,490






Depreciation and amortization 1

29,158






EBITDA

$                     53,078






Business transition costs2

55






Non-cash stock based compensation

7,017






Adjusted EBITDA

$                     60,150






As a percentage of revenue

24.1%












1

Excludes the amortization associated with non-controlling interest.

2

Costs related to acquisition, integration and business transition activities which includes severance, relocation, consulting,
leasehold exit costs, third party merger and acquisitions costs and other costs directly associated with such activities.

 











Reconciliation of First Quarter 2017 Results




GAAP Net Income per Share to Non-GAAP Earnings per Share
















Adjustments


Diluted Earnings Per
Share




(in thousands, except per share data)









GAAP net income



$    12,768


$                     0.22













Business transition costs 1



55






Non-cash interest expense on convertible notes



4,599






Amortization of intangible assets 2



11,738






Tax effect of adjustments 3



(9,123)






Adjustments to GAAP net income



7,269


0.14




Non-GAAP earnings



$    20,037


$                     0.38






















GAAP weighted shares outstanding - diluted





57,786




Non-GAAP weighted shares outstanding - diluted  4





52,683












1

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs,
third party merger and acquisitions costs and other costs directly associated with such activities.

2

Excludes the amortization associated with non-controlling interest.

3

The impact on results from taxes include tax effecting the adjustments above at the statutory rate as well as taking into account discrete items and
including those discrete items in the annual effective tax rate calculation. The Company also includes those adjustments that would have benefited
the tax rate in lieu of the above adjustments as part of the Company's tax filings. The impact of the changes to the tax rate results in an annual
estimated rate of ~35% on a non-GAAP basis.


4

Represents the exclusion of diluted shares associated with the Company's convertible debt and warrant which are economically hedged by the
Company's bond hedge arrangements on both the 2017 and 2021 convertible notes.










Investor Conference Call

NuVasive will hold a conference call today at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the first quarter 2017. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. After the live webcast, the call will remain available on NuVasive's website through May 25, 2017. In addition, a telephone replay of the call will be available until May 2, 2017. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 13658678.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive's highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release or made on the investor conference call referenced herein that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward looking statements. In addition, this news release contains selected financial results from the first quarter 2017, as well as projections for 2017 financial guidance and longer-term financial performance goals. The Company's results for the first quarter 2017 are prior to the completion of review and audit procedures by the Company's external auditors and are subject to adjustment. In addition, the Company's projections for 2017 financial guidance and longer-term financial performance goals represent initial estimates, and are subject to the risk of being inaccurate because of the preliminary nature of the forecasts, the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA™ platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties more fully described in the Company's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

NuVasive, Inc. 

Consolidated Statements of Operations 

(in thousands, except per share data)








Three Months Ended March 31,

(unaudited)


2017


2016

Revenue


$ 249,864


$ 215,104

Cost of goods sold (excluding below amortization of intangible assets)


61,613


54,226

Gross profit


188,251


160,878

Operating expenses:





Sales, marketing and administrative


140,502


124,838

Research and development


12,414


10,629

Amortization of intangible assets


12,061


7,871

Business transition costs


55


5,307

Total operating expenses


165,032


148,645

Interest and other expense, net:





Interest income


137


328

Interest expense


(9,799)


(8,472)

Loss on repurchases of convertible notes



(17,444)

Other income, net


258


50

Total interest and other expense, net


(9,404)


(25,538)

Income (loss) before income taxes


13,815


(13,305)

Income tax (expense) benefit


(1,490)


9,480

Consolidated net income (loss)


$   12,325


$   (3,825)

Add back net loss attributable to non-controlling interest


$      (443)


$      (457)

Net income (loss) attributable to NuVasive, Inc.


$   12,768


$   (3,368)

Net income (loss) per share attributable to NuVasive, Inc.:





Basic


$       0.25


$     (0.07)

Diluted


$       0.22


$     (0.07)

Weighted average shares outstanding:





Basic


50,566


49,617

Diluted


57,786


49,617

 

NuVasive, Inc. 

Consolidated Balance Sheets 

(in thousands, except par values and share amounts) 








March 31, 2017


December 31, 2016

ASSETS


(Unaudited)



Current assets:





Cash and cash equivalents


$          134,008


$                153,643

Accounts receivable, net of allowances of $8,086 and $8,912, respectively


172,103


171,595

Inventory, net


223,075


208,249

Prepaid income taxes


21,161


31,926

Prepaid expenses and other current assets


12,921


10,030

Total current assets


563,268


575,443

Property and equipment, net


203,677


181,524

Intangible assets, net


279,603


291,143

Goodwill


486,342


485,685

Deferred tax assets


5,977


5,810

Restricted cash and investments


7,547


7,405

Other assets


23,721


23,794

Total assets


$       1,570,135


$             1,570,804

LIABILITIES AND EQUITY





Current liabilities:





Accounts payable and accrued liabilities


$            82,467


$                  77,585

Contingent consideration liabilities


48,576


49,742

Accrued payroll and related expenses


38,651


51,000

Income tax liabilities


2,130


2,469

Senior convertible notes


62,486


61,701

Total current liabilities


234,310


242,497

Long-term senior convertible notes


568,939


564,412

Deferred and income tax liabilities, non-current


20,529


18,607

Other long-term liabilities


47,629


44,764

Commitments and contingencies





Stockholders' equity:





Preferred stock, $0.001 par value; 5,000,000 shares authorized, none outstanding



Common stock, $0.001 par value; 120,000,000 shares authorized at March 31, 2017 and December 31, 2016, 55,623,735 and 55,184,660 issued and outstanding at March 31, 2017 and December 31, 2016, respectively


56


55

Additional paid-in capital


1,020,672


1,010,238

Accumulated other comprehensive loss


(8,774)


(10,631)

Accumulated deficit


(65,738)


(66,859)

Treasury stock at cost; 4,963,014 shares and 4,758,828 shares at March 31, 2017 and December 31, 2016, respectively


(252,633)


(237,867)

Total NuVasive, Inc. stockholders' equity


693,583


694,936

Non-controlling interest


5,145


5,588

Total equity


698,728


700,524

Total liabilities and equity


$       1,570,135


$             1,570,804

 

NuVasive, Inc. 

Consolidated Statements of Cash Flows 

(in thousands) 








Three Months Ended March 31,

(unaudited)


2017


2016

Operating activities:





Consolidated net income (loss)


$   12,325


$   (3,825)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:





Depreciation and amortization


29,510


21,224

Loss on repurchases of convertible notes



17,444

Amortization of non-cash interest


5,369


5,112

Stock-based compensation


7,017


4,492

Reserves on current assets


(2,153)


4,162

Other non-cash adjustments


3,013


3,491

Deferred income taxes


1,645


(2,630)

Changes in operating assets and liabilities, net of effects from acquisitions:





Accounts receivable


924


6,939

Inventory


(13,630)


(9,449)

Prepaid expenses and other current assets


(2,756)


1,303

Accounts payable and accrued liabilities


593


10,021

Accrued payroll and related expenses


(12,531)


(9,219)

Income taxes


(1,298)


8,327

Net cash provided by operating activities


28,028


57,392

Investing activities:





Acquisition of Ellipse Technologies, net of cash acquired



(380,674)

Other acquisitions and investments


(2,500)


(8,079)

Purchases of intangible assets


(1,249)


(1,027)

Purchases of property and equipment


(34,545)


(18,279)

Purchases of marketable securities



(36,096)

Proceeds from sales of marketable securities



253,435

Net cash used in investing activities


(38,294)


(190,720)

Financing activities:





Proceeds from the issuance of common stock


410


444

Purchase of treasury stock


(10,356)


(12,599)

Proceeds from issuance of convertible debt, net of issuance costs



634,140

Proceeds from sale of warrants



44,850

Purchase of convertible note hedge



(111,150)

Repurchases of convertible notes



(343,835)

Proceeds from revolving line of credit



50,000

Repayments on revolving line of credit



(50,000)

Other financing activities


(181)


(1,442)

Net cash (used in) provided by financing activities


(10,127)


210,408

Effect of exchange rate changes on cash


758


686

(Decrease) increase in cash and cash equivalents


(19,635)


77,766

Cash and cash equivalents at beginning of period


153,643


192,339

Cash and cash equivalents at end of period


$ 134,008


$ 270,105

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nuvasive-announces-first-quarter-2017-financial-results-300445403.html

SOURCE NuVasive, Inc.

Investor Contact: Suzanne Hatcher, NuVasive, Inc., 858-458-2240, investorrelations@nuvasive.com; Media Contact: Stefanie Mazer, NuVasive, Inc., 858-320-5243, media@nuvasive.com